RAMM Pharma Corp.
RAMM
CNSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.19M | 3.19M | 3.29M | 3.40M | 3.48M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.19M | 3.19M | 3.29M | 3.40M | 3.48M |
| Cost of Revenue | 1.92M | 1.89M | 2.89M | 3.19M | 3.25M |
| Gross Profit | 1.27M | 1.30M | 399.70K | 211.50K | 232.30K |
| SG&A Expenses | 7.52M | 7.78M | 5.33M | 5.37M | 5.17M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 86.30K | 89.10K | 95.40K | 101.30K | 105.40K |
| Total Operating Expenses | 9.53M | 9.76M | 8.31M | 8.66M | 8.53M |
| Operating Income | -6.33M | -6.56M | -5.03M | -5.26M | -5.05M |
| Income Before Tax | -11.19M | -12.10M | -6.53M | -6.58M | -6.17M |
| Income Tax Expenses | -56.90K | 5.90K | 7.10K | 7.10K | 7.10K |
| Earnings from Continuing Operations | -11.13 | -12.11 | -6.54 | -6.59 | -6.18 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.13M | -12.11M | -6.54M | -6.59M | -6.18M |
| EBIT | -6.33M | -6.56M | -5.03M | -5.26M | -5.05M |
| EBITDA | -5.67M | -5.81M | -4.31M | -4.47M | -4.12M |
| EPS Basic | -0.09 | -0.10 | -0.05 | -0.06 | -0.05 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 |
| EPS Diluted | -0.09 | -0.10 | -0.05 | -0.06 | -0.05 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 |
| Average Basic Shares Outstanding | 477.56M | 477.56M | 477.53M | 478.82M | 481.23M |
| Average Diluted Shares Outstanding | 477.56M | 477.56M | 477.53M | 478.82M | 481.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |